MARKET

INKT

INKT

Mink Therapeutics, Inc.
NASDAQ
10.72
+0.21
+2.00%
After Hours: 10.07 -0.65 -6.11% 19:14 05/15 EDT
OPEN
11.09
PREV CLOSE
10.51
HIGH
11.49
LOW
10.18
VOLUME
36.57K
TURNOVER
--
52 WEEK HIGH
76.00
52 WEEK LOW
6.34
MARKET CAP
53.41M
P/E (TTM)
-3.6641
1D
5D
1M
3M
1Y
5Y
1D
Mink Therapeutics’ Earnings Call: High Promise, Tight Runway
TipRanks · 15h ago
MiNK outlines 90-patient randomized Phase II ARDS trial with initial data expected in 2H 2026
Seeking Alpha · 18h ago
Transcript: MiNK Therapeutics Q1 2026 Earnings Conference Call
Benzinga · 1d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 1d ago
MiNK Therapeutics GAAP EPS of -$0.57 beats by $0.20
Seeking Alpha · 1d ago
MiNK Therapeutics' Q1 net loss narrows slightly
Reuters · 1d ago
MiNK Therapeutics Q1 FY26 net loss narrows to $2.74 million
PUBT · 1d ago
*MiNK Therapeutics 1Q Loss/Shr 57c >INKT
Dow Jones · 1d ago
More
About INKT
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.

Webull offers Mink Therapeutics Inc stock information, including NASDAQ: INKT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INKT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INKT stock methods without spending real money on the virtual paper trading platform.